¿ËÈÕ£¬ngµç×ÓÓÎÏ·Á¥ÊôµÚÒ»Ò½ÔºÏû»¯¿Æ¡¢¡¢¾«×¼Ò½Ñ§Ñо¿ÔºÅíËë½ÌÊÚÍŶÓÔÚÃÀ¹ú°©Ö¢Ñо¿Ñ§»áÆÚ¿¯Clinical Cancer ResearchÔÚÏß½ÒÏþÁËÌâΪ¡°The influence of immune heterogeneity on the effectiveness of immune checkpoint inhibitors in multifocal hepatocellular carcinomas¡±µÄÑо¿ÂÛÎÄ¡£¡£¸ÃÑо¿´Ó»ùÒò×鼰ת¼×éˮƽÆÊÎö¶àÔî¸Î°©»¼Õß²î±ð¾Þϸ°©ÔîµÄ»ùÒò×éÌØÕ÷ºÍÃâÒß΢ÇéÐÎÌØÕ÷£¬Õ¹ÏÖÁ˶àÔî¸Î°©²î±ð¾Þϸ°©ÔîµÄÃâÒßÒìÖÊÐÔ¼°Æä¶ÔÃâÒßÖÎÁÆÁÆÐ§µÄÓ°Ïì¡£¡£¸ÃÑо¿ÓÉngµç×ÓÓÎÏ·Ñо¿Õß×ÔÖ÷Íê³É£¬Ïû»¯¿ÆÅíËë½ÌÊÚ¡¢¡¢Ö×Áö¿ÆÐíÀöϼ¸±½ÌÊÚΪ±¾ÎÄÅäºÏͨѶ×÷Õߣ¬Ïû»¯¿Æ»ÆÂüÁᲩʿΪµÚÒ»×÷Õߣ¬ngµç×ÓÓÎÏ·Á¥ÊôµÚһҽԺΪΨһͨѶµ¥Î»£¬¾«×¼Ò½Ñ§Ñо¿ÔºÓÚ¾ý½ÌÊÚΪÂÛÎĵÄÏàÖú×÷Õß¡£¡£
ÍíÆÚ¸Î°©¶ÔPD-1¿¹ÌåµÈÃâÒß¼ì²éµãÒÖÖÆ¼ÁµÄÖÎÁÆ×ÜÌåÏìÓ¦ÂÊȱ·¦20%¡£¡£ÔÚPD-1¿¹ÌåÖÎÁÆÎÞЧµÄ¶àÔî¸Î°©»¼ÕßÖУ¬²¿·Ö»¼Õß¶ÔÃâÒßÖÎÁƱ£´æ»ìÏý·´Ó³£¨²¿·Ö°©ÔîËõС»òÕßÏûÊÅ£¬²¿·Ö°©ÔîÎȹ̻òÕßÔö´ó£©¡£¡£Ô½À´Ô½¶àÖ¤¾ÝÏÔʾ΢ÎÀÐDz»Îȹ̡¢¡¢Ö×ÁöÍ»±ä¸ººÉµÈÒòËØ¿ÉÓ°ÏìÖ×ÁöµÄÃâÒßÖÎÁÆÁÆÐ§£¬¿ÉÊÇ£¬Í³Ò»¸öÌå²î±ð°©ÔîµÄÃâÒßÒìÖÊÐÔ¶ÔÃâÒßÖÎÁƵÄÓ°ÏìÈÔ²»Ã÷È·¡£¡£
ÅíËë½ÌÊÚÍŶӶÔ12Àý¶àÔî¸Î°©»¼ÕßµÄ45¸öÖ×ÁöÑù±¾¼°¶ÔÓ¦°©ÅÔÕý³£×éÖ¯¾ÙÐÐÁËÈ«»ùÒò×é²âÐò¡¢¡¢È«ÍâÏÔ×Ó²âÐò¼°RNA²âÐò¡£¡£Ñо¿·¢Ã÷ͳһ»¼ÕߵĴó°©ÔîºÍС°©ÔîµÄ»ùÒò×éÌØÕ÷±£´æ¼«´óµÄÏàËÆÐÔ£¬°üÀ¨ÏàͬµÄHBV-DNAÕûºÏλµã£¬ÏàËÆµÄȾɫÌå½á¹¹±äÒì¡¢¡¢Í»±äÌØÕ÷¼°¿½±´Êýת±äÇéÐΣ¬ÌáÐÑ12Àý¶àÔî¸Î°©»¼ÕߵĴó°©ÔîºÍС°©ÔîÊôÓÚ¸ÎÄÚ×ªÒÆÁö¡£¡£¸ÃÍŶӽøÒ»²½ÆÊÎö45¸ö°©ÔîµÄÃâÒß΢ÇéÐΣ¬·¢Ã÷ͳһ»¼ÕßÖУ¬Óë´ó°©ÔîÏà±È£¬Ð¡°©Ôî¾ßÓиü¶àµÄÃâÒßϸ°û½þÈó£¬ÃâÒß»îÐԴ̼¤Òò×ÓÒÔ¼°Ô¤²âPD-1¿¹ÌåÖÎÁÆÁÆÐ§µÄ×ÌÈÅËØÏà¹ØÌØÕ÷ÔÚС°©ÔîÖбí´ïÉϵ÷¡£¡£ÃâÒßÏà¹ØÍ¨Â·ÔÚС°©ÔîÖи»¼¯£¬¶øÔöÖ³¼°Ñª¹ÜÌìÉúÏà¹ØÍ¨Â·ÔÚ´ó°©ÔîÖиü¸»¼¯¡£¡£±ðµÄ£¬´ó²¿·ÖС°©Ôî³ÊÏÖsia·ÖÐÍÖеġ°ÃâÒß·´Ó³ÑÇÐÍ¡±¡£¡£ÕâЩЧ¹ûÅú×¢£¬Í³Ò»¸Î°©»¼ÕßµÄС°©Ôî±È´ó°©Ôî¾ßÓиü»îÔ¾µÄÃâÒß״̬¡£¡£
Ϊ½øÒ»²½Ì½ÌÖ²î±ð¾ÞϸµÄ°©Ôî¶ÔPD-1¿¹ÌåÖÎÁÆÊÇ·ñ¾ßÓвî±ðµÄÖÎÁÆÏìÓ¦£¬¸ÃÍŶӶÔ8Àý½ÓÊÜPD-1¿¹ÌåÖÎÁƵĶàÔî¸Î°©»¼ÕßËùÓа©ÔîµÄÃâÒßÖÎÁÆÓ¦´ðÇéÐξÙÐÐÆÀ¹À¡£¡£Ð§¹û·¢Ã÷ÆäÖÐ5Àý¶àÔî¸Î°©»¼ÕߵĴó°©ÔîºÍС°©Ôî¶ÔPD-1¿¹ÌåÖÎÁƱ£´æ»ìÏý·´Ó³£¬¾ùÌåÏÖΪС°©Ôî¾ßÓиüºÃµÄÃâÒßÖÎÁÆÁÆÐ§¡ª¡ªPD-1¿¹ÌåÖÎÁƺó£¬Ð¡°©ÔîÆ½¾ùËõС46.3%£¬¶øÍ³Ò»²¡ÀýµÄ´ó°©ÔîÆ½¾ùÔöÌí14.9%¡£¡£
¸ÃÑо¿¿É²¿·ÖÚ¹ÊÍÁÙ´²ÉÏÃâÒßÖÎÁƵĻìÏý·´Ó³£¬²¢ÎªÁÙ´²ÉϾ«×¼¶¨Î»¸Î°©ÃâÒßÖÎÁÆ»ñÒæÈËȺÌṩÁËÀíÂÛÒÀ¾Ý¡£¡£
ÂÛÎÄÁ´½Ó£º£ºhttps://clincancerres.aacrjournals.org/content/early/2020/06/11/1078-0432.CCR-19-3840